Klaria Pharma Holding AB (OSTO:KLAR) EPS (Basic): kr-0.25 (TTM As of Mar. 2026)


OSTO:KLAR Klaria Pharma Holding AB OSTO:KLAR
28 GF Score
Price kr0.78
GF Value kr0.33
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB EPS (Basic)?

Klaria Pharma Holding AB OSTO:KLAR -1.14% 28 EPS (Basic) is kr-0.25 as of Mar. 2026. GuruFocus rates OSTO:KLAR with a GF Score™ of 28/100 and a GF Value™ of kr0.33 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Klaria Pharma Holding AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr-0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.25.

Klaria Pharma Holding AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.25.

Klaria Pharma Holding AB's EPS without NRI for the three months ended in Mar. 2026 was kr-0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.25.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Klaria Pharma Holding AB  (OSTO:KLAR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Klaria Pharma Holding AB EPS (Basic) Related Terms

Klaria Pharma Holding AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB EPS (Basic) Chart

Klaria Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.94 -1.07 -0.35 -0.38 -0.21

Klaria Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.14 -0.04 -0.03 -0.04
OSTO:KLAR
28GF Score
Klaria Pharma Holding AB OSTO:KLAR
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klaria Pharma Holding AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Klaria Pharma Holding AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-38.887-0)/188.901
=-0.21

Klaria Pharma Holding AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-8.655-0)/245.976
=-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr-0.25 mean?
Klaria Pharma Holding AB (OSTO:KLAR) has a EPS (Basic) of kr-0.25 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Klaria Pharma Holding AB and its competitors.
Is Klaria Pharma Holding AB's EPS (Basic) too high?
Klaria Pharma Holding AB's current EPS (Basic) is kr-0.25. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's EPS (Basic) compare to ZTS?
Klaria Pharma Holding AB's EPS (Basic) of kr-0.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Klaria Pharma Holding AB and its competitors. Klaria Pharma Holding AB's current EPS (Basic) is kr-0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (OSTO:KLAR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.33, compared to a current price of kr0.78 — trading 135.8% above its estimated fair value. The current EPS (Basic) is kr-0.25. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Klaria Pharma Holding AB (OSTO:KLAR), the current EPS (Basic) is kr-0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Klaria Pharma Holding AB (OSTO:KLAR) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of kr0.78 is trading 135.8% above its estimated GF Value™ of kr0.33. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:KLAR:

  • EPS (Basic): kr-0.25
  • GF Value™: kr0.33 vs. price of kr0.78 (135.8% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the OSTO:KLAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Klaria Pharma Holding AB Business Description

Other Exchanges 6FN:Germany
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score

Get the complete analysis for OSTO:KLAR

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.78
Price
kr0.33
GF Value